Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2020-05-10 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
关于股东提前终止减持计划以及减持股份预披露的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company disclosing the termination of a previous share reduction plan and the initiation of a new share reduction plan by certain shareholders. It details the shareholders involved, the number of shares to be reduced, the methods of reduction, and the timing. The content focuses on shareholding changes by insiders and shareholders, specifically about selling shares they hold. There is no financial statement, earnings data, or management discussion. The document is not a full financial report, audit, or earnings release. It is not a regulatory certification or a report publication announcement. The document fits the definition of a Transaction in Own Shares (POS) filing, which reports the company or its shareholders buying back or selling their own shares. The document length is under 5,000 characters, but it contains substantive information about share reduction plans, not just an announcement of a report. Therefore, the best classification is POS with high confidence.
2020-05-10 Chinese
关于公司控股子公司诉讼和解的公告
Legal Proceedings Report Classification · 95% confidence The document is a public announcement from a company regarding the settlement and withdrawal of a lawsuit involving its subsidiary. It details the legal proceedings, the settlement agreement, and the court's dismissal of the case. There is no financial data, no report attached or referenced as being published, and no mention of annual or interim reports. The content focuses solely on legal proceedings and their impact on the company. Therefore, this document fits the category of Legal Proceedings Report (LTR). The document length is short and it is not a report publication announcement or certification. Hence, the classification is LTR with high confidence.
2020-05-07 Chinese
关于召开2019年度股东大会的提示性公告
AGM Information Classification · 100% confidence The document is a detailed announcement about the convening of the 2019 Annual General Meeting (AGM) of the company 贝达药业股份有限公司. It includes information about the meeting date, voting methods (on-site and online), agenda items to be discussed and voted on (including the 2019 annual report, financial statements, profit distribution plan, and other proposals), registration procedures for shareholders, and instructions for proxy voting. The document does not contain the actual annual report or financial statements but rather serves as a notice and instructions for the upcoming AGM. It is not a report itself but an announcement related to the AGM. Therefore, the appropriate classification is AGM Information (AGM-R). The document length (5780 characters) and content confirm it is a full AGM notice rather than a brief report publication announcement or regulatory filing.
2020-05-07 Chinese
关于在研新药BPI-28592获得临床试验通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 贝达药业股份有限公司 regarding the receipt of a clinical trial notification for a new drug BPI-28592 from the National Medical Products Administration (国家药品监督管理局). It details the approval for clinical trials, drug development background, and risk warnings. The document is short (1634 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report but an announcement of a regulatory event related to drug development. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-04-29 Chinese
关于举行2019年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement from 贝达药业股份有限公司 about holding an online performance explanation meeting for the 2019 fiscal year. It references that the full 2019 annual report has already been published on the official disclosure website. The document invites investors to participate in the online meeting where company executives will explain the 2019 performance. The document itself is not the annual report but an announcement of an investor presentation event related to the annual results. Therefore, it fits the category of Investor Presentation (IP). The document length is short and it does not contain financial statements or detailed analysis, so it is not the report itself but an announcement of a presentation event.
2020-04-27 Chinese
关于股东提前终止减持计划以及减持股份预披露的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by a company regarding the early termination of a shareholder's stock reduction plan and the pre-disclosure of another shareholder's planned stock reduction. It details the shareholders involved, the number of shares to be reduced, the methods of reduction, and compliance with relevant securities laws and regulations. The content focuses on shareholding changes and disclosures related to share sales by significant shareholders. There is no financial report, earnings data, or management discussion. The document is not a report itself but an official announcement about shareholding changes and reduction plans by shareholders. Therefore, it fits best under the category of Major Shareholding Notification (MRQ). The document length is under 5,000 characters, but it contains substantive information about shareholding changes, not just a report publication announcement or a regulatory filing. Hence, MRQ is the most appropriate classification with high confidence.
2020-04-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.